Remynd could receive as much as $413m from healthcare firm Novo Nordisk if its ReS39 diabetes treatment is proven to be effective.
Remynd, a Germany-based medical research spinout from KU Leuven, has concluded a licence agreement with healthcare firm Novo Nordisk to develop its treatment for diabetes.
Remynd could receive as much as €350m ($413m) in research and milestone payments, as well as a royalty on any eventual sales.
The deal covers Remynd’s ReS39 diabetes treatment, which aims to induce greater insulin production within animals with type 1 and 2 diabetes. Diabetes is caused by insulin deficiency and impaired control of glucose…